Nick Paul Taylor

Biography for Nick Paul Taylor

Nick Taylor, UK Correspondent

Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at and follow him on Twitter at @NickPaulTaylor.

Articles by Nick Paul Taylor

Smallpox vaccination leads to sexually transmitted infection

A man vaccinated against smallpox passed on a milder form of the disease to a sexual partner, the Center for Disease Control and Prevention reports.

EMA opens debate on pig products in vaccines

The European Medicines Agency has opened a debate on the safe use of animal-derived products in vaccines. Publication of the draft guidelines comes three years after the discovery of pig-virus DNA in vaccines from GlaxoSmithKline ($GSK) and Merck ($MRK) prompted a regulatory rethink.

Study pins cancer vaccine failures on self-sabotaging adjuvant

The history of cancer vaccines is littered with candidates that showed great promise in the lab, only to flunk clinical trials. Now, scientists think they know why--the vaccines are self-sabotaging.

Sequester cuts set to hit vaccines

Deep federal spending cuts triggered by sequestration are set to rock vaccine development and administration in the U.S. and beyond. The White House warns that the cuts will limit the number of vaccines federal agencies buy from GlaxoSmithKline ($GSK), Merck ($MRK), Sanofi ($SNY) and other manufacturers.

UPDATED: GSK lawsuit shows risks of vaccine outsourcing

GlaxoSmithKline is suing Hospira for more than $25 million in damages over the quality of influenza vaccine supplies for the U.S. market. In the lawsuit, GSK alleges that Hospira hit quality problems and cancelled the contract three years before it was due to end.

Novartis encouraged by typhoid vaccine progress

Novartis has talked up the prospects of its typhoid vaccine candidate after completing Phase II safety studies. A wider rollout is now being considered as Novartis pushes to develop a vaccine to eliminate a disease that still kills 200,000 people a year.